ID NUAK2_HUMAN Reviewed; 628 AA. AC Q9H093; DT 25-JUL-2006, integrated into UniProtKB/Swiss-Prot. DT 01-MAR-2001, sequence version 1. DT 27-MAR-2024, entry version 176. DE RecName: Full=NUAK family SNF1-like kinase 2; DE EC=2.7.11.1; DE AltName: Full=Omphalocele kinase 2; DE AltName: Full=SNF1/AMP kinase-related kinase; DE Short=SNARK; GN Name=NUAK2 {ECO:0000312|EMBL:AAH17306.1}; Synonyms=OMPHK2, SNARK; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] {ECO:0000305} RP NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 205-224, FUNCTION, ACTIVITY RP REGULATION, PHOSPHORYLATION AT THR-208, AND MUTAGENESIS OF THR-208. RX PubMed=14976552; DOI=10.1038/sj.emboj.7600110; RA Lizcano J.M., Goeransson O., Toth R., Deak M., Morrice N.A., Boudeau J., RA Hawley S.A., Udd L., Maekelae T.P., Hardie D.G., Alessi D.R.; RT "LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, RT including MARK/PAR-1."; RL EMBO J. 23:833-843(2004). RN [2] {ECO:0000305, ECO:0000312|EMBL:CAB66825.1} RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Testis {ECO:0000312|EMBL:CAB66825.1}; RX PubMed=11230166; DOI=10.1101/gr.gr1547r; RA Wiemann S., Weil B., Wellenreuther R., Gassenhuber J., Glassl S., RA Ansorge W., Boecher M., Bloecker H., Bauersachs S., Blum H., Lauber J., RA Duesterhoeft A., Beyer A., Koehrer K., Strack N., Mewes H.-W., RA Ottenwaelder B., Obermaier B., Tampe J., Heubner D., Wambutt R., Korn B., RA Klein M., Poustka A.; RT "Towards a catalog of human genes and proteins: sequencing and analysis of RT 500 novel complete protein coding human cDNAs."; RL Genome Res. 11:422-435(2001). RN [3] {ECO:0000305, ECO:0000312|EMBL:BAC11234.1} RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Teratocarcinoma {ECO:0000312|EMBL:BAC11234.1}; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] {ECO:0000312|EMBL:AAH17306.1} RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Lymph {ECO:0000312|EMBL:AAH17306.1}; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [5] {ECO:0000305} RP FUNCTION. RX PubMed=14575707; DOI=10.1016/j.bbrc.2003.09.184; RA Suzuki A., Kusakai G., Kishimoto A., Minegichi Y., Ogura T., Esumi H.; RT "Induction of cell-cell detachment during glucose starvation through F- RT actin conversion by SNARK, the fourth member of the AMP-activated protein RT kinase catalytic subunit family."; RL Biochem. Biophys. Res. Commun. 311:156-161(2003). RN [6] {ECO:0000305} RP FUNCTION, AUTOPHOSPHORYLATION, AND MUTAGENESIS OF LYS-81. RX PubMed=15345718; DOI=10.1074/jbc.m404334200; RA Legembre P., Schickel R., Barnhart B.C., Peter M.E.; RT "Identification of SNF1/AMP kinase-related kinase as an NF-kappaB-regulated RT anti-apoptotic kinase involved in CD95-induced motility and invasiveness."; RL J. Biol. Chem. 279:46742-46747(2004). RN [7] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-435; SER-523; SER-544 AND RP SER-547, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [8] RP FUNCTION. RX PubMed=19927127; DOI=10.1038/emboj.2009.342; RA Humbert N., Navaratnam N., Augert A., Da Costa M., Martien S., Wang J., RA Martinez D., Abbadie C., Carling D., de Launoit Y., Gil J., Bernard D.; RT "Regulation of ploidy and senescence by the AMPK-related kinase NUAK1."; RL EMBO J. 29:376-386(2010). RN [9] RP ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=22814378; DOI=10.1073/pnas.1210303109; RA Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A., RA Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E., RA Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.; RT "N-terminal acetylome analyses and functional insights of the N-terminal RT acetyltransferase NatB."; RL Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012). RN [10] RP INVOLVEMENT IN ANPH2, VARIANT ANPH2 138-TYR--GLN-145 DELINS GLU, RP CHARACTERIZATION OF VARIANT ANPH2 138-TYR--GLN-145 DELINS GLU, FUNCTION, RP AND PHOSPHORYLATION AT THR-208. RX PubMed=32845958; DOI=10.1084/jem.20191561; RA Bonnard C., Navaratnam N., Ghosh K., Chan P.W., Tan T.T., Pomp O., RA Ng A.Y.J., Tohari S., Changede R., Carling D., Venkatesh B., Altunoglu U., RA Kayserili H., Reversade B.; RT "A loss-of-function NUAK2 mutation in humans causes anencephaly due to RT impaired Hippo-YAP signaling."; RL J. Exp. Med. 217:0-0(2020). RN [11] RP VARIANTS [LARGE SCALE ANALYSIS] SER-309; LEU-341; ARG-503; VAL-516 AND RP GLU-541. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Stress-activated kinase involved in tolerance to glucose CC starvation. Induces cell-cell detachment by increasing F-actin CC conversion to G-actin. Expression is induced by CD95 or TNF-alpha, via CC NF-kappa-B. Protects cells from CD95-mediated apoptosis and is required CC for the increased motility and invasiveness of CD95-activated tumor CC cells. Phosphorylates LATS1 and LATS2. Plays a key role in neural tube CC closure during embryonic development through LATS2 phosphorylation and CC regulation of the nuclear localization of YAP1 a critical downstream CC regulatory target in the Hippo signaling pathway (PubMed:32845958). CC {ECO:0000269|PubMed:14575707, ECO:0000269|PubMed:14976552, CC ECO:0000269|PubMed:15345718, ECO:0000269|PubMed:19927127, CC ECO:0000269|PubMed:32845958}. CC -!- CATALYTIC ACTIVITY: CC Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl- CC [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:14575707, ECO:0000269|PubMed:14976552}; CC -!- CATALYTIC ACTIVITY: CC Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L- CC threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, CC Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, CC ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; CC EC=2.7.11.1; Evidence={ECO:0000269|PubMed:14575707, CC ECO:0000269|PubMed:14976552}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC Evidence={ECO:0000269|PubMed:14575707, ECO:0000269|PubMed:14976552}; CC -!- ACTIVITY REGULATION: Activated by phosphorylation on Thr-208. CC {ECO:0000269|PubMed:14976552}. CC -!- INTERACTION: CC Q9H093; Q4V328: GRIPAP1; NbExp=3; IntAct=EBI-1181722, EBI-717919; CC Q9H093; P31947: SFN; NbExp=2; IntAct=EBI-1181722, EBI-476295; CC Q9H093; P62258: YWHAE; NbExp=2; IntAct=EBI-1181722, EBI-356498; CC -!- PTM: Phosphorylated at Thr-208 by STK11/LKB1 in complex with STE20- CC related adapter-alpha (STRADA) pseudo kinase and CAB39 CC (PubMed:14976552). Autophosphorylation is also possible at Thr-208 CC (PubMed:32845958). {ECO:0000269|PubMed:14976552, CC ECO:0000269|PubMed:32845958}. CC -!- DISEASE: Anencephaly 2 (ANPH2) [MIM:619452]: A form of anencephaly, an CC extreme neural tube defect resulting in the absence of brain tissues, CC and death in utero or perinatally. Infants are born with intact spinal CC cords, cerebellums, and brainstems, but lack formation of neural CC structures above this level. The skull is only partially formed. ANPH2 CC features may also include frontonasal dysplasia with midline cleft of CC the upper lip and alveolar ridge, bifid nose, and clinical CC anophthalmia. ANPH2 inheritance is autosomal recessive. CC {ECO:0000269|PubMed:32845958}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK Ser/Thr CC protein kinase family. SNF1 subfamily. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AL136891; CAB66825.1; -; mRNA. DR EMBL; AK074830; BAC11234.1; -; mRNA. DR EMBL; BC017306; AAH17306.1; -; mRNA. DR CCDS; CCDS1453.3; -. DR RefSeq; NP_112214.2; NM_030952.2. DR AlphaFoldDB; Q9H093; -. DR SMR; Q9H093; -. DR BioGRID; 123581; 48. DR IntAct; Q9H093; 41. DR STRING; 9606.ENSP00000499251; -. DR BindingDB; Q9H093; -. DR ChEMBL; CHEMBL5698; -. DR DrugBank; DB11936; Bempedoic acid. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; Q9H093; -. DR GuidetoPHARMACOLOGY; 2130; -. DR GlyGen; Q9H093; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q9H093; -. DR PhosphoSitePlus; Q9H093; -. DR BioMuta; NUAK2; -. DR DMDM; 74761376; -. DR CPTAC; CPTAC-2844; -. DR CPTAC; non-CPTAC-2947; -. DR EPD; Q9H093; -. DR jPOST; Q9H093; -. DR MassIVE; Q9H093; -. DR MaxQB; Q9H093; -. DR PaxDb; 9606-ENSP00000356125; -. DR PeptideAtlas; Q9H093; -. DR ProteomicsDB; 80220; -. DR Antibodypedia; 2090; 296 antibodies from 30 providers. DR DNASU; 81788; -. DR Ensembl; ENST00000367157.6; ENSP00000356125.5; ENSG00000163545.11. DR GeneID; 81788; -. DR KEGG; hsa:81788; -. DR MANE-Select; ENST00000367157.6; ENSP00000356125.5; NM_030952.3; NP_112214.3. DR UCSC; uc001hce.4; human. DR AGR; HGNC:29558; -. DR CTD; 81788; -. DR DisGeNET; 81788; -. DR GeneCards; NUAK2; -. DR HGNC; HGNC:29558; NUAK2. DR HPA; ENSG00000163545; Tissue enhanced (esophagus, vagina). DR MalaCards; NUAK2; -. DR MIM; 608131; gene. DR MIM; 619452; phenotype. DR neXtProt; NX_Q9H093; -. DR OpenTargets; ENSG00000163545; -. DR Orphanet; 563609; Isolated anencephaly. DR PharmGKB; PA142671243; -. DR VEuPathDB; HostDB:ENSG00000163545; -. DR eggNOG; KOG0611; Eukaryota. DR GeneTree; ENSGT00940000158422; -. DR HOGENOM; CLU_000288_63_42_1; -. DR InParanoid; Q9H093; -. DR OMA; RPLMKKQ; -. DR OrthoDB; 5475340at2759; -. DR PhylomeDB; Q9H093; -. DR TreeFam; TF324572; -. DR PathwayCommons; Q9H093; -. DR SignaLink; Q9H093; -. DR SIGNOR; Q9H093; -. DR BioGRID-ORCS; 81788; 14 hits in 1190 CRISPR screens. DR ChiTaRS; NUAK2; human. DR GeneWiki; NUAK2; -. DR GenomeRNAi; 81788; -. DR Pharos; Q9H093; Tchem. DR PRO; PR:Q9H093; -. DR Proteomes; UP000005640; Chromosome 1. DR RNAct; Q9H093; Protein. DR Bgee; ENSG00000163545; Expressed in cervix squamous epithelium and 144 other cell types or tissues. DR GO; GO:0031588; C:nucleotide-activated protein kinase complex; IBA:GO_Central. DR GO; GO:0005524; F:ATP binding; IDA:UniProtKB. DR GO; GO:0000287; F:magnesium ion binding; IDA:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0030036; P:actin cytoskeleton organization; IDA:UniProtKB. DR GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW. DR GO; GO:0042149; P:cellular response to glucose starvation; IDA:UniProtKB. DR GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central. DR GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB. DR GO; GO:0032007; P:negative regulation of TOR signaling; IBA:GO_Central. DR GO; GO:0034504; P:protein localization to nucleus; IMP:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0035330; P:regulation of hippo signaling; IMP:UniProtKB. DR CDD; cd14161; STKc_NUAK2; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR24346; MAP/MICROTUBULE AFFINITY-REGULATING KINASE; 1. DR PANTHER; PTHR24346:SF101; NUAK FAMILY SNF1-LIKE KINASE 1; 1. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. DR Genevisible; Q9H093; HS. PE 1: Evidence at protein level; KW Acetylation; Apoptosis; ATP-binding; Direct protein sequencing; KW Disease variant; Kinase; Magnesium; Metal-binding; Nucleotide-binding; KW Phosphoprotein; Reference proteome; Serine/threonine-protein kinase; KW Transferase. FT CHAIN 1..628 FT /note="NUAK family SNF1-like kinase 2" FT /id="PRO_0000247756" FT DOMAIN 53..303 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 355..493 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 531..562 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 371..401 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 175 FT /note="Proton acceptor" FT /evidence="ECO:0000250|UniProtKB:O60285, FT ECO:0000255|PROSITE-ProRule:PRU00159, ECO:0000255|PROSITE- FT ProRule:PRU10027" FT BINDING 59..67 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000250|UniProtKB:O60285, FT ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 81 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000269|PubMed:15345718" FT MOD_RES 1 FT /note="N-acetylmethionine" FT /evidence="ECO:0007744|PubMed:22814378" FT MOD_RES 208 FT /note="Phosphothreonine; by LKB1" FT /evidence="ECO:0000269|PubMed:14976552, FT ECO:0000269|PubMed:32845958" FT MOD_RES 435 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19369195" FT MOD_RES 523 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19369195" FT MOD_RES 544 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19369195" FT MOD_RES 547 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19369195" FT MOD_RES 573 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q8BZN4" FT VARIANT 138..145 FT /note="YDYISERQ -> E (in ANPH2; no effect on protein FT abundance; loss of protein serine/threonine kinase FT activity; loss of autophosphorylation at T-208; loss of FT function in regulation of hippo signaling)" FT /evidence="ECO:0000269|PubMed:32845958" FT /id="VAR_086106" FT VARIANT 309 FT /note="T -> S (in dbSNP:rs55745939)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040964" FT VARIANT 341 FT /note="R -> L (in dbSNP:rs35208615)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040965" FT VARIANT 503 FT /note="K -> R (in an ovarian Endometrioid carcinoma sample; FT somatic mutation; dbSNP:rs1271546767)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040966" FT VARIANT 516 FT /note="A -> V (in dbSNP:rs35070935)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040967" FT VARIANT 541 FT /note="G -> E (in a breast pleomorphic lobular carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040968" FT MUTAGEN 81 FT /note="K->R: Loss of autophosphorylation, kinase activity FT and of anti-apoptotic activity." FT /evidence="ECO:0000269|PubMed:15345718" FT MUTAGEN 208 FT /note="T->A: Prevents phosphorylation and activation by FT STK11/LKB1 complex." FT /evidence="ECO:0000269|PubMed:14976552" SQ SEQUENCE 628 AA; 69612 MW; F76F8B1BF94F4C87 CRC64; MESLVFARRS GPTPSAAELA RPLAEGLIKS PKPLMKKQAV KRHHHKHNLR HRYEFLETLG KGTYGKVKKA RESSGRLVAI KSIRKDKIKD EQDLMHIRRE IEIMSSLNHP HIIAIHEVFE NSSKIVIVME YASRGDLYDY ISERQQLSER EARHFFRQIV SAVHYCHQNR VVHRDLKLEN ILLDANGNIK IADFGLSNLY HQGKFLQTFC GSPLYASPEI VNGKPYTGPE VDSWSLGVLL YILVHGTMPF DGHDHKILVK QISNGAYREP PKPSDACGLI RWLLMVNPTR RATLEDVASH WWVNWGYATR VGEQEAPHEG GHPGSDSARA SMADWLRRSS RPLLENGAKV CSFFKQHAPG GGSTTPGLER QHSLKKSRKE NDMAQSLHSD TADDTAHRPG KSNLKLPKGI LKKKVSASAE GVQEDPPELS PIPASPGQAA PLLPKKGILK KPRQRESGYY SSPEPSESGE LLDAGDVFVS GDPKEQKPPQ ASGLLLHRKG ILKLNGKFSQ TALELAAPTT FGSLDELAPP RPLARASRPS GAVSEDSILS SESFDQLDLP ERLPEPPLRG CVSVDNLTGL EEPPSEGPGS CLRRWRQDPL GDSCFSLTDC QEVTATYRQA LRVCSKLT //